News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
145 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37190)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53929)
2023 (42568)
2024 (37443)
2025 (28807)
Month
January (2935)
February (2968)
March (2707)
April (2905)
May (3623)
June (2409)
July (2086)
August (2588)
September (2381)
October (3062)
November (1143)
Day
2 (21)
3 (150)
4 (290)
5 (296)
6 (241)
7 (145)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
Day
2
3
4
5
6
7
Opinion
The GLP-1 Paradox—Why Is a $95B Obesity Market Ignoring Its Biggest Problem?
The nausea and other gastrointestinal side effects of weight loss drugs like Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound will limit how much these drugs can help patients and stunt the overall obesity market unless we approach the problem head on.
November 7, 2025
·
5 min read
·
James O’Mara
Approvals
J&J Wins Expansion for Top-Selling Cancer Drug in First for Smoldering Multiple Myeloma
Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of progression to active disease.
November 7, 2025
·
2 min read
·
Tristan Manalac
Gene therapy
Patient Dies After Receiving Intellia’s CRISPR Gene Therapy Candidate
The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex-z.
November 7, 2025
·
2 min read
·
Tristan Manalac
IgA nephropathy
Vera Builds ‘Compelling Profile’ for Atacicept in IgAN, Eyes Q4 Filing
The Phase III results impressed Guggenheim Partners analysts both in terms of efficacy and safety. If approved, atacicept would become the first APRIL/BAFF inhibitor for IgAN to make it to the market.
November 7, 2025
·
2 min read
·
Tristan Manalac
Vaccines
Pesky ‘Macro Factors’—aka RFK Jr.—Come for Vaccine Pharmas’ Wallets
Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all suffering revenue hits to their vaccine programs.
November 7, 2025
·
4 min read
·
Annalee Armstrong
Mergers & acquisitions
Novo CEO Fires Back at Pfizer From White House: ‘Put Your Hand in Your Pocket’
During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ongoing bidding war between Novo Nordisk and Pfizer over obesity biotech Metsera.
November 7, 2025
·
2 min read
·
Annalee Armstrong
Mergers & acquisitions
Pfizer Wins Metsera Bidding War Over Novo With Final $10B Price Tag
After a bidding war erupted between Pfizer and Novo Nordisk over the fledgling obesity drugmaker, Metsera sided with its original suitor in a final agreement announced late Friday evening.
November 7, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Novo Nordisk’s CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
November 7, 2025
·
8 min read
Press Releases
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
November 7, 2025
·
15 min read
Press Releases
Dr. Judith Hartmann to Become New Chief Financial Officer of Bayer AG
November 7, 2025
·
4 min read
1 of 15
Next